Under construction – not a live service
Sign in
Taking people in United StatesNo phase

Clinical Applications of Advanced Ophthalmic Imaging

Key facts

Where
Miami, United StatesSee the site

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 99 years old?

Where in United States

  • Bascom Palmer Eye InstituteMiami, United StatesTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
University of Miami
Trial code
NCT03135327
Record updated
16 September 2026
Original description
The purpose of this study is to determine the clinical application of advanced ophthalmic imaging devices such as optical coherence tomography (OCT), retinal function imager (RFI), slit-lamp biomicroscopy (SLB), PERG in diseased eyes and normal controls.Read full original descriptionShow less

The purpose of this study is to determine the clinical application of advanced ophthalmic imaging devices such as optical coherence tomography (OCT), retinal function imager (RFI), slit-lamp biomicroscopy (SLB), PERG in diseased eyes and normal controls.

There are two phases in this study. The first phase is an observational phase which studies the eye in various conditions. The second phase is an interventional phase which studies the changes in the eyes after taking an over-the-counter medical food (Ocufolin) for 6 months.

Inclusion: Self-reported normal healthy subjects; Clinical diagnosis of Alzheimer's Disease, mild cognitive impairment, multiple sclerosis, dry eye, myopia, diabetics and stroke; Who can keep the eye open for imaging; The participant will be eligible for entry in the study if s/he:; Is at least 18 years old and has full legal capacity to volunteer; Has read and signed the IRB Informed Consent Document; Is willing and able to follow participant instructions; Has clear corneas and crystalline lens; Initial visual acuities were 20/80 or better; MTHFR C677TT homozygous, or MTHFR C677T/A1298C compound heterozygous with mild to moderate micro-aneurismal vascular retinopathy disease; Hemoglobin A1c is 10 or less; Normotensive with or without medications; Without retinal capillary dropout or macular edema; Blood homocysteine > 9.

Exclusion: who can not receiving ophthalmic imaging; Has had surgery or an eye injury within 6 months; Has an active ocular disease; who can not read and sign the ICF; who cannot tolerate bright light during imaging; Interventional Phase 2 Group:; The subjects will be ineligible for entry into the study if s/he:.

Observational Phase 1 Group.

ClinicalTrials.gov NCT03135327